Alto Neuroscience continues march toward the clinic with Series B, hoping to unveil data next year
A year ago, Alto Neuroscience came into the game with a $32 million Series A and plans to launch three Phase IIa trials for several psychiatric disorders, including treatment-resistant depression and PTSD. The company, founded by Stanford neurologist Amit Etkin, was built around predictive technology that his team said could predict PTSD patients’ response to therapy by just looking at brainwaves.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.